OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trial The Phase 2 trial is designed as a randomized, placebo ...

OKYO Pharma has initiated the Phase II trial of OK-101, a treatment for neuropathic corneal pain (NCP), by dosing the first subject. This marks a significant advancement in addressing a condition ...

A total of 48 patients are planned to enroll for the study, with NCP disease confirmed via confocal microscopy. The primary endpoint of this study is to measure pain relief using Visual Analog ...

The NCP is part of the Mahayuti alliance, which also includes the Bharatiya Janata Party (BJP) and Eknath Shinde-led Shiv Sena. So far, the BJP has declared candidates for 99 seats, and Shinde’s ...

Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan disease OKYO is the first company to have an IND application granted by the FDA for NCP ...

He is one of the world’s foremost experts on NCP and treats patients with ocular pain from across the United States and worldwide. His previous research has demonstrated safety and efficacy of ...

Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan disease OKYO is the first company to have an IND application granted by the FDA for NCP The ...

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trial The Phase 2 trial is designed as a randomized, placebo-controlled, ...

A total of 48 patients are planned to enroll for the study, with NCP disease confirmed via confocal microscopy. The primary endpoint of this study is to measure pain relief using Visual Analog Scale ...